Skip to main content

Advertisement

Table 8 Summary of studies that examined the safety of treatment interventions for people with diabetes

From: Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review

Study Design Subjects Infection Organism Intervention Assessment (week)
Gupta [42] RCT Itraconazole N = 35 Sex = 16 M; 19 F Age = 57.77 (2.3) yr Terbinafine N = 35 Sex = 18 M; 17 F Age = 63.65 (1.9) yr DLSO Dermatophyte Ciclopirox 8% Ciclopirox 8% nail lacquer applied to nail and 5 mm surrounding skin. Daily application over the previous coat, removed after 7 days using isopropyl alcohol. Nails trimmed and debrided at each scheduled visit (8 weeks) 48
Brenner [43] Case series N = 49 Sex = 36 M; 13 F Age = 63.8 (12.0) yr Duration of diabetes = 8.4 (7.4) yr Duration of infection = 10.8 (15.3) yr DSO†† Not reported Terbinafine 250 mg terbinafine daily 12 weeks 48
Farkas [46] Case series N = 89 Sex = 47 M; 42 F Age = 55.7 (11.7) yr Duration of diabetes = 10.2 (7.7) Duration of infection = 5.4 (6.0) DSO Dermatophyte (67.4%); moulds (5.6%); yeast (4.5%) Itraconazole pulse therapy 200 mg of oral itraconazole taken twice a day for the first week of three consecutive months Terbinafine 250 mg of oral terbinafine once daily for 12 weeks. 48
Sadighha [41] Case series N = 13 Sex = NR Age = NR DSO†† Dermatophyte Pulse itraconazole therapy 200 mg of oral itraconazole taken twice a day for the first week of four consecutive months 26
  1. Concomitant tinea pedis was present.
  2. "DSO" = distal subungual onychomycosis; "DLSO" = distal lateral subungual onychomycosis
  3. Study 4 is excluded from the graph because efficacy was not assessed at week 48 like the rest of the studies. Sadighha [41] found itraconazole achieved cure in 7.7% (1/13) of patients with diabetes at week 26